Allakos Drops After Early-stage Results for Lead Asset

Seeking Alpha02:34

JMP Securities Reiterates Market Outperform on Allakos, Maintains $3 Price Target

JMP Securities analyst Jonathan Wolleben reiterates Allakos (NASDAQ:ALLK) with a Market Outperform and maintains $3 price target.

Benzinga00:01

TD Cowen Maintains Allakos(ALLK.US) With Hold Rating

TD Cowen analyst Joseph Thome maintains $Allakos(ALLK.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 36.3% and a total average return of -10.0% over the past yea

Futu NewsJun 26 20:33 · Ratings

LifeSci Capital Maintains Allakos(ALLK.US) With Hold Rating

LifeSci Capital analyst Sam Slutsky maintains $Allakos(ALLK.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 44.0% and a total average return of 4.6% over the past

Futu NewsJun 26 20:33 · Ratings

JMP Securities Maintains Allakos(ALLK.US) With Buy Rating, Maintains Target Price $3

JMP Securities analyst Jonathan Wolleben maintains $Allakos(ALLK.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 42.7% and a

Futu NewsJun 26 12:32 · Ratings

Allakos Shares Are Trading Lower. The Company Announced Results From the Single and Multiple Ascending Phase 1 Study of Intravenous AK006 in Healthy Volunteers.

Allakos Shares Are Trading Lower. The Company Announced Results From the Single and Multiple Ascending Phase 1 Study of Intravenous AK006 in Healthy Volunteers.

BenzingaJun 26 04:30